Peptidream Inc. has reported that an early-phase clinical trial for 64Cu-PD-32766, a 64Cu-labeled radiopharmaceutical targeting carbonic anhydrase IX (CAIX), for patients with clear cell renal cell carcinoma has been approved by the clinical review board of the National Cancer Center Hospital East in Japan.
Researchers from Haisco Pharmaceutical Group Co. Ltd. presented the discovery and preclinical characterization of a brain-penetrating BRAF paradox breaker, HSK-42360, being developed for the treatment of BRAF-driven cancers. HSK-42360 proved to be a potent BRAF V600E inhibitor (IC50=5 nM) with selectivity over wild-type BRAF.